Immunotherapy, Innate Immunity, Chronic Inflammatory Disorders, Cancer, Metabolic Bone Diseases, Translational Research, Biotechnology
Dr. Shirin Kalyan is an Adjunct Professor with the Department of Medicine at University of British Columbia, the Scientist leading the Answer Factory at BC Children’s Hospital Research Institute, and the Director of Scientific Innovation at Qu Biologics, a clinical-stage Vancouver based biotech with an innovative immunotherapy platform that uses bugs as drugs to treat immune-related diseases. She earned her PhD from the University of British Columbia in Experimental Medicine investigating the pivotal innate immune mediators of inflammation in the context of toxic shock syndrome. As a Humboldt Fellow, Dr. Kalyan spent three years at the Institute of Immunology in Kiel understanding how bisphosphonates, the standard of care for bone loss and osteolytic bone disease, affect immune function and antioxidant capacity. Her research interests include determining how to optimally support immune function in the context of cancer and chronic inflammatory diseases and understanding how drug therapies commonly used to treat chronic degenerative disorders affect immune integrity.
1. Kalyan S*, Goshtesabi A, Sarray S, Joannou A , Almawi W. Assessing C-reactive protein/albumin ratio as a new predictor of Polycystic Ovary Syndrome: a case-control study (*corresponding author). BMJ Open 2018;8:e021860. doi: 10.1136/bmjopen-2018-021860
2. Sham HP, Bazett M, Bosiljcic M, Yang H, Luk B, Law HT, Morampudi V, Yu HB, Pankovich J, Sutcliffe S, Bressler B, Marshall JK, Fedorak RN, Chen J, Jones M, Gunn H, Kalyan S*, and Vallance BA*. Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis (*corresponding authors). Frontiers in Immunology. 2018, Sep 27. https://doi.org/10.3389/fimmu.2018.02211
3. Brajic TS, Berger C, Schlammerl K, Macdonald H, Kalyan S, Hanley DA, Adachi JD, Kovacs CS, Prior JC (CaMos Research Group). Combined hormonal contraceptives use and bone mineral density changes in adolescent and young women in a prospective population-based Canada-wide observational study. Journal of Musculoskeletal and Neuronal Interactions. 2018, Jun 1;18(2):227-236.
4. Kalyan S, Pick N, Mai A, Murray MCM, Kidson K, Chu J, Albert AYK, Côté HCF, Maan EJ, Goshtasebi A, Money DM, Prior JC. Premature Spinal Bone Loss in Women Living with HIV is Associated with Shorter Leukocyte Telomere Length. International Journal of Environmental Research and Public Health, 2018, 15, 1018.
5. Bazett M, Costa A, Bosiljcic M, Anderson R, Alexander M, Wong S, Dhanji S, Chen, Pankovich J, Lam S, Sutcliffe S, Gunn H, Kalyan S*, and Mullins D*. Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. 2018, 7:3. OncoImmunology. (*corresponding authors)
6. Prior JC, Prior JC, Seifert-Klauss VR, Giustini D, J.D. Adachi, Kalyan S, Goshtasebi A. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. Journal of Musculoskeletal and Neuronal Interactions. 2017, Sep 1;17(3):146-154.
7. Kalyan S*, Patel M, Kingwell E, Cote H, Liu D, Prior JC. Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll. Scientific Reports, 2017, 7, Article number: 3432 (*corresponding author)
8. Bazett M, Biala A, Huff R, Zeglinski, Hansbro, Bosiljcic M, Gunn H, Kalyan S, Hirota JA. Attenuating TH1-skewed immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation. Respiratory Research, 2017, May 18(1):92
9. Bazett M, Biala A, Huff R, Bosiljcic M, Gunn H, Kalyan S, Hirota JA. A novel microbe-based treatment that attentuates the inflammatory profile in a mouse model of allergic airway disease. Scientific Reports, 2016, Oct 13. doi:10.1038/srep35338
10. Kalyan S. It may seem inflammatory, but some T cells are innately healing to the bone. Journal of Bone and Mineral Research, 2016, May 21. doi: 10.1002/jbmr.2875.
11. Kalyan S, Wang J, Quabius ES, Huck J, Wiltfang J, Baines JF, Kabelitz D. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. Journal of Translational Medicine, 2015, July; 13:212-225. doi:10.1186/s12967-015-0568-z
• Ranked as most highly accessed by BMC Journal of Translational Medicine
12. Chandrasekaran V*, Kalyan S*, Biehl V, Lettau M, Nerdal PT, Oberg H-H, Wesch D, Lindhorst T, Kabelitz D. Novel synthesis of fluorochrome-coupled zoledronate with preserved functional activity on gamma/delta T cells and tumor cells. MedChemComm, 2015, advance online publication March 30. doi: 10.1039/C5MD00063G (*equal contribution)
13. Wang J, Kalyan S, Steck N, Turner L, Harr B, Künzel S, Vallier M, Häsler R, Franke A, Oberg H-H, Ibrahim S, Grassl G, Kabelitz D, Baines J. Analysis of intestinal microbiota in hybrid house mice reveals evolutionary divergence in a vertebrate hologenome. Nature Communications, 2015, Mar; article #6440. doi: 10.1038/ncomms7440
14. Fazio J, Kalyan S, Wesch D, Kabelitz D. Inhibition of human γδ T cell proliferation and effector functions by neutrophil serine proteases. Scandinavian Journal of Immunlogy. 2014, Dec;80(6):381-9. doi: 10.1111/sji.12221
15. Kalyan S*, Huebbe P, Esatbeyoglu T, Niklowitz P, Côté HCF, Rimbach G, Kabelitz D. Nitrogen-bisphosphonate therapy linked to compromised coenzyme Q10 and vitamin E status in postmenopausal women. Journal of Clinical Endocrinology and Metabolism. 2014, Apr;99(4):1307-13. doi: 10.1210/jc.2013-3648. Epub 2014 Jan 13. (*corresponding author)
16. Kalyan S, & Kabelitz D. When neutrophils meet T cells: beginnings of a tumultuous relationship with under-appreciated potential. European Journal of Immunology. 2014, Mar;44(3):627-33. doi: 10.1002/eji.201344195. Epub 2014 Feb 10.
17. Kalyan S*, Chandrasekaran V, Quabius ES, Lindhorst TK, and Kabelitz D. Nitrogen-bisphosphonate uptake by neutrophils leads to the suppression of human peripheral blood γδ T cells. Cellular and Molecular Life Sciences. 2014, Jun;71(12):2335-46. [Epub ahead of print 2013 Oct 26] (*corresponding author)
• featured in Human Immunology News: http://connexoncreative.com/publications/archives/HIN134.aspx
18. Fazio J, Quabius ES, Müller A, Adam-Klages S, Wesch D, Sebens S, Kalyan S, Lamprecht P, Kabelitz D. Vδ2 T cell deficiency in granulomatosis with polyangiitis (Wegener’s granulomatosis). Clinical Immunology. 2013, Oct;149(1):65-72.
19. Kabelitz D, Kalyan S, Oberg H, Wesch D. Human Vdelta2 versus non-Vdelta2 gamma delta T cells in tumor immunity. OncoImmunology. 2013, 2:e23304; http://dx.doi.org.
20. Kalyan S*, Quabius ES, Wiltfang J, Mönig H, Kabelitz D. Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug-effects of aminobisphosphonate therapy. Journal of Bone and Mineral Research, 2013; Apr;28(4):728-35. (*corresponding author)
• Featured story in JBMR, DOI: 10.1002/jbmr.1886 and Nature Publishing’s BoneKEy Reports BoneKEy Reports 2, doi:10.1038/bonekey.2013.61
21. Kalyan S*, & Kabelitz D. Defining the nature of human γδ T cells: A biographical sketch of the highly empathetic. Cellular and Molecular Immunology, 2013; Jan;10(1):21-9. (*corresponding author)
22. Sathi P, Kalyan S, Hitchcock CL, Pudek M and Prior JC. Progesterone Therapy increases Free Thyroxine Levels—data from a randomized placebo-controlled 12-week hot flush trial. Clinical Endocrinology (Oxf). 2013; Aug;79(2):282-7.
- 01/2011 – 12/2012 Humboldt Fellowship – Alexander von Humboldt Foundation (Germany)
- 04/2001 – 08/2005 Doctoral Scholarship – Michael Smith Foundation of Health Research
- May 2003 Best Oral Presentation – Department of Experimental Medicine
- 04/2001 – 05/2004 Doctoral Scholarship – Canadian Institutes of Health Research
- 09/1995 – 05/1999 Outstanding Student Initiative – University of British Columbia
- Rare Disease Foundation (Microgrant Program)
- Providence Health Care (Research Challenge Program)
- NSERC Engage (for Qu Biologics)
MEDI501: Topics in Translational Research (Experimental Medicine Program)